louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04707170: MRI Exploration of Meningeal Inflammatory Disease
Official title: MRI Exploration of Meningeal Inflammatory Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: MRI
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2021-01-13
Enrollment: 302
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients presenting for imaging for whom an MRI examination with gadolinium injection has been prescribed and who meet the inclusion and non-inclusion criteria will be offered to participate in the study.

The patients included, hospitalized at the A. de Rothschild Foundation Hospital for at least 24 hours, may be included in the ancillary study to meet secondary objective number 5

Brief summary: Patients who have agreed to participate in the study will complete the MRI protocol as part of routine care, to which two additional sequences of 6 minutes duration will be added.

The MRI of routine care includes at least the following sequences:

* 3D T1 TFE 1.0 isotropic (2 minutes)
* T2 TSE (2 minutes)
* 3D FLAIR pre-injection (opt) (3 minutes)
* 3D FLAIR post-injection (3 minutes)

As part of the research, the following sequences will be acquired:

* FABIR pre-injection (3 minutes)
* FABIR post-injection (3 minutes)

Patients hospitalized for a foreseeable duration of at least 24 hours will be offered participation in the longitudinal tab of the study, for which four non-injected MRI examinations will be performed. The examinations will be carried out remotely from the injected MRI (1h, 2h, 12h-15h, 24h-36h). These exams dedicated to research will include the following sequences for a maximum of 8 minutes:

* 3D T1 TFE 1.0 isotropic (2 minutes)
* 3D FLAIR (3 minutes)
* FABIR (3 minutes)


Eligibility criteria: Inclusion Criteria:

* Patient over 18 years old
* To benefit as part of his treatment of an MRI with injection of gadolinium
* Express consent to participate in the study
* Affiliate or beneficiary of a social security scheme

For the ancillary study to meet secondary endpoint number 5:

* Patient over 18 years old
* To benefit as part of his treatment of an MRI with injection of gadolinium
* Hospitalized for an expected period of at least 48 hours after the time of inclusion
* Express consent to participate in the study
* Affiliate or beneficiary of a social security scheme

Exclusion Criteria:

* Patient benefiting from a legal protection measure
* Pregnant or breastfeeding woman

Primary outcomes:
measure: detection of meningeal contrast enhancement with the flair sequence
timeFrame: 1 DAY
measure: detection of meningeal contrast enhancement with the FABIR sequence
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Hhopital fondation adolphe de rothschild
Study officials:
affiliation: Hôpital fondation Adolphe de Rothschild
name: julien savatovsky
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01137370: The Impact of Vitamin D on Tuberculosis Among Koreans
Official title: The Impact of Vitamin D Level and Single Nucleotide Polymorphisms of Vitamin D Receptor Gene on the Development and Treatment Response of Tuberculosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tuberculosis
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2010-06-04
Enrollment: 203
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients diagnosed and treated as having a TB in Seoul National University Hospital

Brief summary: Vitamin D has been regarded to be beneficial to tuberculosis (TB) patients. The aim of this study is to elucidate the role of vitamin D deficiency in development and treatment outcomes among Korean TB patients. Furthermore, the impact of genotypes of vitamin D receptor gene on TB development will also be evaluated.


Eligibility criteria: Inclusion Criteria:

* older than 19 years
* diagnosed and treated having a tuberculosis

Exclusion Criteria:

* positive HIV antibody

Primary outcomes:
measure: Prevalence of Vitamin D Deficiency
timeFrame: At enrollment
measure: Median 25-OHD Level
timeFrame: August 2010 to March 2011
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT03032770: Early Prediction of Placenta Accreta by Ultrasound and Color Doppler
Official title: Early Prediction of Placenta Accreta by 2 Dimensional Transvaginal Ultrasound and Color Doppler
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Placenta Accreta
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-01-26
Enrollment: 148
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: first trimester pregnancy between 11 weeks and 13 weeks.

Brief summary: Placenta accreta is a substantially life threatening condition and one of the causes of maternal morbidity and mortality in the world. According to study done in United Kingdom, The estimated incidence of placenta accreta/increta/percreta was 1.7 per 10,000 maternities overall and 577 per 10,000 in women with both a previous cesarean delivery and placenta previa. in a tertiary south Italian center, The incidence increased from 0.12% during the 1970s, to 0.31% during the 2000s.While in United States of America, the prevalence of placenta accreta was 3.7 per 1000 deliveries.


Eligibility criteria: Inclusion Criteria:

1. Low implantation of the gestational sac (\<4 cm from external os) by transvaginal ultrasound
2. Presence of placental lakes by transvaginal ultrasound
3. Disruption of placental-myometrial interface by transvaginal ultrasound
4. Trophoblast overlapping a uterine scar (Cesarean section, myomectomy) by transvaginal ultrasound
5. Intraplacental dilated vessels by Doppler ultrasound
6. Turbulent blood flows by Doppler ultrasound
7. Greatly increased periplacental vascularity by Doppler ultrasound

Exclusion Criteria:

a) Cases far away from our hospital and expected to be lost to be followed. b) Pregnant women who will refuse to Participate

-

Primary outcomes:
measure: Confirmation of occurrence of placenta accreta during delivery.
timeFrame: duration of pregnancy
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut University
Study officials:
References:
Clinical trial NCT04449770: Height-based Formula for Predicting the Insertion Depth of Left-sided Double and the Role of Fiberoptic Bronchoscopy
Official title: A Study on the Use of an Established Novel Height-based Formula for Predicting the Insertion Depth of Left-sided Double and the Role of Fiberoptic Bronchoscopy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Thoracic Anesthesia
Keywords: Thoracic anesthesia
Double lumen tube
Height based formula
Lead sponsor: King Saud University
Sponsor class: OTHER
First posted: 2020-06-29
Enrollment: 70
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients aged 20-60 yr undergoing thoracic surgery with the use of left-sided DLT for lung isolation

Brief summary: The use of height based formula to predict insertion depth of left-sided double lumen tube in thoracic surgery is now well established. The investigators have developed a formula to be used and published recently. The investigators verified the formula with the use of FOB. This observational study we are going to use with FOB checking if needed.

Detailed description: The use of a height-based formula to predict the insertion depth of left-sided double-lumen tubes in thoracic surgery is now well established. The investigators have developed a formula to be used and published recently. The investigators verified the formula with the use of FOB. This observational study will use FOB checking if needed.

Our hypothesis is that DLT can insert without the use of FOB in most of the cases. That doesn't mean FOB is less required.

Eligibility criteria: Inclusion Criteria:

* patients whose procedure required placement of an LDLT

Exclusion Criteria:

* patients with intraluminal bronchial lesions and patients with a difficult airway.

Primary outcomes:
measure: correct position of DLT with proper lung deflation without use of FOB
timeFrame: during surgical time
Secondary outcomes:
Other outcomes:
Locations:
city: Riyadh
country: Saudi Arabia
facility: King Saud University
Study officials:
References:
Clinical trial NCT00890370: Should Any One Airway Clearance Technique be Recommended for People With Cystic Fibrosis?
Official title: A Comparison of Five Airway Clearance Techniques in the Treatment of Adults With Cystic Fibrosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cystic Fibrosis
Keywords: Cystic fibrosis
Airway clearance
Lead sponsor: Royal Brompton & Harefield NHS Foundation Trust
Sponsor class: OTHER
First posted: 2009-04-29
Enrollment: 75
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study was to evaluate the long term effects, over one year, of five airway clearance techniques used by people with cystic fibrosis (active cycle of breathing techniques, autogenic drainage, positive expiratory pressure and oscillating positive expiratory pressure (R-C Cornet and Flutter)). The primary outcome measure was forced expiratory volume in one second (FEV1)and the null hypothesis was that there are no differences among the regimens.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of cystic fibrosis (genotype or sweat sodium concentration greater than 70 mmol/litre)
* Forced expiratory volume in one second greater than or equal to 25% predicted, on assessment for entry to the study.

Exclusion Criteria:

* Evidence of a current respiratory exacerbation (Thornton et al 2004)
* Current severe haemoptysis
* Past history of pneumothorax
* Awaiting lung / heart-lung transplantation
* Pregnancy
* Recent (within 3 months) acquisition of Burkholderia cepacia

Primary outcomes:
measure: Forced expiratory volume in one second (FEV1)
timeFrame: 48 weeks
Secondary outcomes:
measure: Quality of life (Short Form-36 and Chronic Respiratory Questionnaire)
timeFrame: 48 weeks
measure: Exercise capacity (Modified shuttle test)
timeFrame: 48 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Royal Brompton & Harefield NHS Foundation Trust
name: Jennifer A Pryor, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03412370: Questionnaires and Cognitive Assessments Following Mammography
Official title: Symptom Tracking in Women Following Mammography
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Health Status Unknown
Lead sponsor: University of Southern California
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2018-01-26
Enrollment: 6
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women who have just completed a mammography

Brief summary: This pilot research trial studies how well questionnaires and cognitive assessments work in tracking patient symptoms following mammography. Gathering information over time through questionnaires and cognitive tests about symptoms patients may experience after a mammogram may help doctors understand the cause of these symptoms.

Detailed description: PRIMARY OBJECTIVES:

I. To determine the feasibility of Internet-based cognitive assessments as preliminary data prior to larger clinical trial.

OUTLINE:

Patients complete questionnaires and cognitive assessments over 45-60 minutes within 3 weeks following mammography and at about 3 months in patients for whom biopsy is not required, before biopsy and at about 3 months in patients for whom biopsy is required, and at 4-6 weeks after first chemotherapy infusion in patients receiving chemotherapy.

Eligibility criteria: Inclusion Criteria:

* Mammography Breast Imaging Reporting and Data System (BI-RAD) 4-5; or BI-RAD 1-2
* Fluent in English
* Access to Internet
* Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

* Prior abnormal mammography
* Prior cancer diagnosis
* Prior treatment with chemotherapy

Primary outcomes:
measure: Number of patients invited who agree to participate
timeFrame: Up to 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: USC / Norris Comprehensive Cancer Center
state: California
Study officials:
affiliation: University of Southern California
name: Joan Broderick, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05055570: Angiotensin II Pathway and Postoperative Hypoxemia
Official title: The Mechanism Research of Angiotensin II Pathway and Postoperative Hypoxemia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aortic Dissection
Lead sponsor: Beijing Anzhen Hospital
Sponsor class: OTHER
First posted: 2021-09-24
Enrollment: 88
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing surgical treatment for acute type A aortic dissection in our hospital were selected. The age was 18 years ≤ age ≤80years, and gender was not limited. The overall study patients were divided into the hypoxemia group and non-hypoxemia group according to the presence or lack of hypoxemia after surgery.

Brief summary: Acute type A aortic dissection is often accompanied by postoperative hypoxemia, the cause of which is not fully understood. Angiotensin II is an important component of the renin-angiotensin system (RAS), which has been suggested to be involved in the development of aortic dissection and pulmonary inflammation.The purpose of this study was to investigate the role and mechanism of angiotensin II pathway in postoperative hypoxemia after acute type A aortic dissection, and to provide reference for clinical application


Eligibility criteria: Inclusion Criteria:

* patients undergoing surgery for acute type A aortic dissection
* age between 18 to 80

Exclusion Criteria:

* perioperative severe cardiac insufficiency
* rejection of consent

Primary outcomes:
measure: The Difference Concentrations of ANG II in Serum Between Patients With and Without Postoperative Hypoxemia.
timeFrame: Within 24 hours after surgery
Secondary outcomes:
measure: The Risk Factors for Postoperative Hypoxemia in Stanford Type A Acute Aortic Dissection Patients.
timeFrame: up to 60 days
measure: Duration of Stay in the Intensive Care Unit
timeFrame: up to 60 days
Other outcomes:
Locations:
city: Beijing
country: China
facility: Anzhen hospital, Beijing
state: Beijing
Study officials:
References:
Clinical trial NCT04250870: Physical Fitness in Elderly
Official title: COMPARISON OF THE PHYSICAL FITNESS LEVELS IN NURSING HOME RESIDENTS AND COMMUNITY DWELLING ELDERLY PEOPLE
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aging
Healthy Aging
Physical Fitness
Keywords: aging
community dwelling
health
nursing homes
physical fitness
Lead sponsor: Baskent University
Sponsor class: OTHER
First posted: 2020-01-31
Enrollment: 118
Sex: ALL
Minimum age (years): 65
Maximum age (years): 90
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized clinical trial
Primary purpose: OTHER

Brief summary: Aging decreases the physical fitness levels in living beings. The environmental factors also have a major effect on the physical fitness levels. The objective of this study was to compare the physical fitness levels of nursing home residents and community-dwelling elderly people. This study employed 118 participants, who consisted of nursing home residents and community-dwelling elderly people. The physical fitness levels of the elderly people were measured by Senior Fitness Test. The physical fitness levels of the elderly people were measured by Senior Fitness Test. Chair stand test, arm curl test, 2-minute step test, chair sit and reach test, back-scratch test, 8-foot up and go test and body mass index were measured.


Eligibility criteria: Inclusion Criteria:

1. Aged between 65 and 85 years
2. Scored between 24 and 30 points in the Mini-Mental Status Examination (MMSE).
3. Living in nursing homes for at least six months (for nursing home residents) (6,7).

Exclusion Criteria:

1. Not able to communicate verbally
2. Not able to stand for at least 90 seconds and ambulated with assistance
3. Patients with severe visual impairment, neurological disorders and/or congestive heart failure
4. Individuals who are not advised exercise.

Primary outcomes:
measure: 2-minute step test
timeFrame: 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Baskent University
Study officials:
References:
Clinical trial NCT00770770: Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina
Official title: A Randomized, Double-masked, Pilot Study of the Safety and Efficacy of 0.5 µg/Day and 0.2 µg/Day Iluvien™ (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg in Subjects With Macular Edema Secondary to Retinal Vein Occlusion
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Macular Edema
Retinal Vein Occlusion
Keywords: Macular edema secondary to RVO
Lead sponsor: Alimera Sciences
Sponsor class: INDUSTRY
First posted: 2008-10-10
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will assess the safety and efficacy of FA Intravitreal Inserts in subjects with macular edema secondary to RVO.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of macular edema due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)
* Central subfield thickness \> 300 μm
* BCVA of ≥ 24 and ≤ 68 letters
* Males and non-pregnant females 18 years and over

Exclusion Criteria:

* Macular edema secondary to any condition other than RVO
* Presence of foveal atrophy, dense pigmentary changes or dense subfoveal exudates in the study eye
* Cystic intraretinal hemorrhage involving the fovea in the study eye that is responsible for vision loss
* Glaucoma or ocular hypertension (IOP \> 21 mmHg or concurrent therapy at screening with IOP-lowering agents)
* Any prior treatment with intravitreal, subtenon, or periocular steroid or anti-VEGF therapy since the diagnosis of RVO in the study eye
* Any change in systemic steroid therapy within 3 months of screening
* History of vitrectomy in the study eye

Primary outcomes:
measure: Visual Acuity
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lexington
country: United States
facility: University of Kentucky Department of Ophthalmology
state: Kentucky
city: Boston
country: United States
facility: Ophthalmic Consultants of Boston
state: Massachusetts
city: Cleveland
country: United States
facility: Cole Eye Institute
state: Ohio
Study officials:
References:
Clinical trial NCT02143570: Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women
Official title: Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Overactive Bladder
Keywords: Urinary Bladder, Overactive
Darifenacin
Physiotherapy
Quality of Life
Lead sponsor: Universidad de Valparaiso
Sponsor class: OTHER
Collaborators: name: Recalcine (GynoPharm)
First posted: 2014-05-21
Enrollment: 80
Sex: FEMALE
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Overactive bladder is a common problem among adult women. Darifenacin is an antimuscarinic drug that is frequently used as part of the management of the condition. However, current evidence backing its use is limited. This study aims to address Darifenacin's effectiveness in adjunct to physiotherapy in treating symptoms due to overactive bladder.


Eligibility criteria: Inclusion Criteria:

* Patients with overactive bladder as diagnosed and confirmed by a urologist.
* Able to answer the ICIC, King's Health Questionnaire and Overactive Bladder Questionnaire.
* Able and willing to receive urodynamic studies.

Exclusion Criteria:

* History of pelvic radiotherapy.
* Recent pelvic surgery (\<1 year).
* History of anti-incontinence surgery.
* Pregnancy.

Primary outcomes:
measure: Quality of Life
timeFrame: 12 weeks
Secondary outcomes:
measure: Overactive Bladder Symptoms
timeFrame: 12 weeks
measure: Adverse Events
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Valparaiso
country: Chile
facility: Hospital Carlos Van Buren
Study officials:
affiliation: Senior Urologist
name: Melissa Cifuentes, M.D.
role: PRINCIPAL_INVESTIGATOR
References: